BridgeMD
New treatment option for Chronic Pulmonary Aspergillosis
Official title Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
ClinicalTrials.gov ID: NCT05653193
What this study is testing
- What it's testing
- This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung disease like Chronic Obstructive Lung Disease (COPD) or previously treated tuberculosis (TB).
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of CPA
- Started antifungal treatment for CPA within the last 8 weeks and received no antifungals for CPA in the 8 weeks prior
- Chest CT scan available within the 6 months prior to enrolment
- Individuals of child bearing potential agree to have pregnancy test an use highly effective contraception
You likely can't join if
- Moderate to severe liver dysfunction (Child-Pugh Class B or C)
- Renal failure (eGFR \<30 mL/min)
- Clinically diagnosed active depression
- Active tuberculosis or non-tuberculous mycobacterial (NTM) lung disease
- Acute infection or other event within the preceding 4 weeks which, as assessed by the investigators, might interfere with the assessment of response...
- Use of any interferon formulation within the preceding six months
See the full eligibility criteria
- Diagnosis of CPA
- Started antifungal treatment for CPA within the last 8 weeks and received no antifungals for CPA in the 8 weeks prior
- Chest CT scan available within the 6 months prior to enrolment
- Individuals of child bearing potential agree to have pregnancy test an use highly effective contraception
- Moderate to severe liver dysfunction (Child-Pugh Class B or C)
- Renal failure (eGFR \<30 mL/min)
- Clinically diagnosed active depression
- Active tuberculosis or non-tuberculous mycobacterial (NTM) lung disease
- Acute infection or other event within the preceding 4 weeks which, as assessed by the investigators, might interfere with the assessment of response to treatment
- Use of any interferon formulation within the preceding six months
- Active viral hepatitis infection
- Pregnancy or breastfeeding
- Immunosuppression (\>15mg prednisolone/day for at least four weeks or equivalent) within the preceding six months
- Inability to self-administer subcutaneous medications AND lack of a carer who can administer
- Participants lacking capacity to consent
The study team makes the final eligibility decision.
Where it's taking place
- Manchester, United Kingdom
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Manchester, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.